viimane versioon :
19/11/2024
Infostab
ingredientide nimekiri
nimekiri
Sobivus otsing
Y-liini sobivuse tabel
Viited
uurimisrühmad
valistab
plakat
Sidemed
sponsorid
Autor
Kasutusjuhend
ajakiri
Viited 4102
tüüp :
ajaleht
uurimisrühmad :
Auckland - Faculty of Medical and Health Sciences, University of Auckland
Autor :
Svirskis D, Behera S, Naidoo N, Beachman J, Raina T, Zhou Y, Berkahn L, Costello I, Gu Y.
pealkiri :
Stability of vincristine sulfate, doxorubicin hydrochloride and etoposide phosphate admixtures in polyisoprene elastromeric pump supporting transition of the EPOCH regimen to oupatient care.
publikatsioon :
J Oncol Pharm Practice ;25,4:831-840. 2018
Tõendite tase :
füüsikaline stabiilsus :
Keemiline püsivus :
Muud meetodid :
Kommentaarid :
ingredientide nimekiri
Doxorubicin hydrochloride
Etoposide phosphate
Vincristine sulfate
2-6°C
Vincristine sulfate
0,005 mg/ml
Doxorubicin hydrochloride
0,12 mg/ml
Etoposide phosphate
0,6 mg/ml
14
2-6°C
Vincristine sulfate
0,01 mg/ml
Doxorubicin hydrochloride
0,24 mg/ml
Etoposide phosphate
1,2 mg/ml
14
2-6°C
Vincristine sulfate
0,016 mg/ml
Doxorubicin hydrochloride
0,4 mg/ml
Etoposide phosphate
2 mg/ml
14
35°C
Vincristine sulfate
0,005 mg/ml
Doxorubicin hydrochloride
0,12 mg/ml
Etoposide phosphate
0,6 mg/ml
7
35°C
Vincristine sulfate
0,01 mg/ml
Doxorubicin hydrochloride
0,24 mg/ml
Etoposide phosphate
1,2 mg/ml
7
35°C
Vincristine sulfate
0,016 mg/ml
Doxorubicin hydrochloride
0,4 mg/ml
Etoposide phosphate
2 mg/ml
7
Mentions Légales
